|
IVAN
|
announcement from a third party'verification of configuration data...this...
|
|
IPHAF
|
once we hit 1.80 you would see the sell-off again....we do something to get...
|
|
IPHAF
|
divest together with " transplant indications " ...what else do...
|
|
IPHAF
|
I don't think Roche will opt out if THE SCIENCE IS GOOD...Cellcept isn...
|
|
IPHAF
|
Snrkid, am glad that you re keeping your level of optimism alive..
The...
|
|
IPHAF
|
If I am correct, they are trying to increase the patient enrolment in Europe...
|
|
IPHAF
|
this is all monkey business !...Stanford has immuno supprsessive drug trials...
|
|
IPHAF
|
I would spend a couple of millions to jack up the market price ( call it...
|
|
IPHAF
|
Phase3 Psoriasis European interim results will be out in next few months. By...
|
|
IPHAF
|
I didn't expect Old timer would come back in around 1.65...he would have...
|
|
IPHAF
|
The deal with Lux Biosciences will pay ISA 32 million dollars...Uveitis is...
|
|
IPHAF
|
" A Phase II Study of BMS-224818 (Belatacept) in Patients Who Have...
|
|
IPHAF
|
There are quite a few in the market like Neoral , SanCya, Gereric Cylosporine...
|
|
IPHAF
|
This new version isn't better than the old in terms of its potency/safety...
|
|
IPHAF
|
..it looks we are heading towards the $2 barrier and break loose..those who...
|
|
IPHAF
|
I think Dr. Randall Morris has been experimenting with monkey for too long at...
|
|
IPHAF
|
As far as I know nobody has said ISA247 would take over the transplant market...
|
|
IPHAF
|
the article you posted is about a phase2 trial result as below:
"...
|
|
IPHAF
|
good find...they are still in early stage....some safety issues derived form...
|
|
IPHAF
|
" what are we worth with roche versus what we are worth without them.
...
|